Anti-Alpha-synuclein [VH14 (NAC14)], Rabbit IgG-Fc Fusion,

Absolute Antibody

Anti-Alpha-synuclein [VH14 (NAC14)], Rabbit IgG-Fc Fusion,

9

The fusion of a proteasome-targeting PEST motif to this intrabody enhanced the solubility of the nanobody in cytoplasm and significantly enhanced degradation of the target protein, alpha-syn-GFP (PMID: 22929188). The in vivo therapeutic potential of gene therapy for delivery of proteasome-directed nanobodies selectively targeting alpha-syn was evaluated in a synuclein overexpression-based PD model. Post-mortem assessments of the substantia nigra (SN) of Sprague-Dawley rats after intracellular delivery of VH14-PEST showed that it markedly reduced the level of phosphorylated Serine-129 alpha-syn labeling relative to saline-treated animals (PMID: 30155513). A bifunctional antibody generated by fusing VH14 to a proteosome-targeting signal was able to counteract heterologous proteostatic effects of mutant alpha-Syn on mutant huntingtin Exon1 and protect against alpha-Syn toxicity using propidium iodide or Annexin V readouts (PMID: 27824888).

Functional Assay

Research Use Only

Monoclonal

VH14 (NAC14)

SNCA

synuclein alpha

NACP, PARK1, PARK4, PD1, alpha-synuclein, I+/--synuclein, non A-beta component of AD amyloid, synuclein alpha-140, synuclein, alpha (non A4 component of amyloid precursor)

Rabbit

IgG

Alpha-synuclein

This chimeric rabbit antibody was made using the variable domain sequences of the original Human VHH format, for improved compatibility with existing reagents, assays and techniques.

Human

-20°C,2°C to 8°C

41116161